Skip to main content
Top
Published in: Abdominal Radiology 2/2018

01-02-2018

Characterizing indeterminate liver lesions in patients with localized pancreatic cancer at the time of diagnosis

Authors: Manav Bhalla, Mohammed Aldakkak, Naveen M. Kulkarni, Stacy D. O’Connor, Michael O. Griffin Jr., Kathleen K. Christians, Douglas B. Evans, Susan Tsai, Parag P. Tolat

Published in: Abdominal Radiology | Issue 2/2018

Login to get access

Abstract

Background

In patients with newly diagnosed pancreatic cancer, the classification of indeterminate liver lesions is an unanswered clinical dilemma as misclassification of these lesions can impact the assignment of clinical stage and subsequent treatment planning. Our objective was to design a standardized classification system to more accurately define the risk of malignancy in indeterminate liver lesions.

Methods

In this retrospective study, patients with localized, non-metastatic pancreatic cancer were identified and pre-treatment computed tomography (CT) scans were evaluated for the presence or absence of liver lesions. Liver lesions were defined as definitely benign (1) or indeterminate (2). Indeterminate lesions were further sub-classified as either indeterminate probably benign (2B) or indeterminate possibly malignant (2M). The index liver lesion was evaluated on follow-up imaging for stability or unequivocal disease progression.

Results

From 2008 to 2015, 304 patients with localized, non-metastatic pancreatic cancer were identified and 125 (41%) patients had liver lesions. Of the 125 patients, the liver lesions in 35 (28%) were classified as definitely benign and in 90 (72%) patients they were classified as indeterminate. The 90 patients with indeterminate lesions included 80 (89%) classified as indeterminate probably benign (2B) and 10 (11%) classified as indeterminate possibly malignant (2M). After a median follow-up of 56 weeks, no patient with a definitely benign lesion had metastatic disease progression of the index lesion. Of the 90 patients with indeterminate liver lesions, the index lesion progressed to unequivocal liver metastasis in 8 (9%) patients; 5 (6%) of the 80 lesions classified as indeterminate probably benign (2B), and 3 (30%) of the ten lesions classified as indeterminate possibly malignant (2M). The sensitivity of the classification system was 38% and the specificity was 91%. The positive predictive value was 30% and the negative predictive value was 94%.

Conclusions

A significant proportion of patients with localized pancreatic cancer will have liver lesions identified at the time of diagnosis and most of these lesions will have indeterminate characteristics. A classification system which further stratifies indeterminate liver lesions by malignant potential can assist clinicians in determining optimal treatment plan and is associated with a high negative predictive value.
Literature
2.
go back to reference Horton KM, Fishman EK (2002) Adenocarcinoma of the pancreas: CT imaging. Radiol Clin North Am 40(6):1263–1272CrossRefPubMed Horton KM, Fishman EK (2002) Adenocarcinoma of the pancreas: CT imaging. Radiol Clin North Am 40(6):1263–1272CrossRefPubMed
3.
go back to reference Liu RC, Traverso LW (2005) Diagnostic laparoscopy improves staging of pancreatic cancer deemed locally unresectable by computed tomography. Surg Endosc 19(5):638–642CrossRefPubMed Liu RC, Traverso LW (2005) Diagnostic laparoscopy improves staging of pancreatic cancer deemed locally unresectable by computed tomography. Surg Endosc 19(5):638–642CrossRefPubMed
4.
go back to reference Satoi S, Yanagimoto H, Toyokawa H, et al. (2011) Selective use of staging laparoscopy based on carbohydrate antigen 19-9 level and tumor size in patients with radiographically defined potentially or borderline resectable pancreatic cancer. Pancreas 40(3):426–432CrossRefPubMed Satoi S, Yanagimoto H, Toyokawa H, et al. (2011) Selective use of staging laparoscopy based on carbohydrate antigen 19-9 level and tumor size in patients with radiographically defined potentially or borderline resectable pancreatic cancer. Pancreas 40(3):426–432CrossRefPubMed
5.
go back to reference Somers I, Bipat S (2017) Contrast-enhanced CT in determining resectability in patients with pancreatic carcinoma: a meta-analysis of the positive predictive values of CT. Eur Radiol 27(8):3408–3435CrossRefPubMedPubMedCentral Somers I, Bipat S (2017) Contrast-enhanced CT in determining resectability in patients with pancreatic carcinoma: a meta-analysis of the positive predictive values of CT. Eur Radiol 27(8):3408–3435CrossRefPubMedPubMedCentral
6.
go back to reference Tsai S, Evans DB (2016) Therapeutic advances in localized pancreatic cancer. JAMA Surg 151:862–868CrossRefPubMed Tsai S, Evans DB (2016) Therapeutic advances in localized pancreatic cancer. JAMA Surg 151:862–868CrossRefPubMed
7.
go back to reference Schwartz LH, Gandras EJ, Colangelo SM, Ercolani MC, Panicek DM (1999) Prevalence and importance of small hepatic lesions found at CT in patients with cancer. Radiology 210(1):71–74CrossRefPubMed Schwartz LH, Gandras EJ, Colangelo SM, Ercolani MC, Panicek DM (1999) Prevalence and importance of small hepatic lesions found at CT in patients with cancer. Radiology 210(1):71–74CrossRefPubMed
8.
go back to reference Khalil HI, Patterson SA, Panicek DM (2005) Hepatic lesions deemed too small to characterize at CT: prevalence and importance in women with breast cancer. Radiology 235(3):872–878CrossRefPubMed Khalil HI, Patterson SA, Panicek DM (2005) Hepatic lesions deemed too small to characterize at CT: prevalence and importance in women with breast cancer. Radiology 235(3):872–878CrossRefPubMed
9.
go back to reference Evans DB, George B, Tsai S (2015) Non-metastatic pancreatic cancer: resectable, borderline resectable, and locally advanced-definitions of increasing importance for the optimal delivery of multimodality therapy. Ann Surg Oncol 22(11):3409–3413CrossRefPubMed Evans DB, George B, Tsai S (2015) Non-metastatic pancreatic cancer: resectable, borderline resectable, and locally advanced-definitions of increasing importance for the optimal delivery of multimodality therapy. Ann Surg Oncol 22(11):3409–3413CrossRefPubMed
10.
go back to reference Evans DB, Varadhachary GR, Crane CH, et al. (2008) Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol 26(21):3496–3502CrossRefPubMed Evans DB, Varadhachary GR, Crane CH, et al. (2008) Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol 26(21):3496–3502CrossRefPubMed
11.
go back to reference Raman SP, Horton KM, Fishman EK (2012) Multimodality imaging of pancreatic cancer-computed tomography, magnetic resonance imaging, and positron emission tomography. Cancer J 18(6):511–522CrossRefPubMed Raman SP, Horton KM, Fishman EK (2012) Multimodality imaging of pancreatic cancer-computed tomography, magnetic resonance imaging, and positron emission tomography. Cancer J 18(6):511–522CrossRefPubMed
12.
go back to reference Appel BL, Tolat P, Evans DB, Tsai S (2012) Current staging systems for pancreatic cancer. Cancer journal. 18(6):539–549CrossRef Appel BL, Tolat P, Evans DB, Tsai S (2012) Current staging systems for pancreatic cancer. Cancer journal. 18(6):539–549CrossRef
13.
go back to reference Al-Hawary MM, Francis IR, Chari ST, et al. (2014) Pancreatic ductal adenocarcinoma radiology reporting template: consensus statement of the Society of Abdominal Radiology and the American Pancreatic Association. Gastroenterology 146(1):291–304CrossRefPubMed Al-Hawary MM, Francis IR, Chari ST, et al. (2014) Pancreatic ductal adenocarcinoma radiology reporting template: consensus statement of the Society of Abdominal Radiology and the American Pancreatic Association. Gastroenterology 146(1):291–304CrossRefPubMed
14.
go back to reference Jones EC, Chezmar JL, Nelson RC, Bernardino ME (1992) The frequency and significance of small (less than or equal to 15 mm) hepatic lesions detected by CT. AJR Am J Roentgenol 158(3):535–539CrossRefPubMed Jones EC, Chezmar JL, Nelson RC, Bernardino ME (1992) The frequency and significance of small (less than or equal to 15 mm) hepatic lesions detected by CT. AJR Am J Roentgenol 158(3):535–539CrossRefPubMed
15.
go back to reference Expert Panel on Gastrointestinal I, Kaur H, Hindman NM, et al. (2017) ACR appropriateness criteria(R) suspected liver metastases. J Am Coll Radiol 14(5S):S314–S325 Expert Panel on Gastrointestinal I, Kaur H, Hindman NM, et al. (2017) ACR appropriateness criteria(R) suspected liver metastases. J Am Coll Radiol 14(5S):S314–S325
16.
go back to reference Krakora GA, Coakley FV, Williams G, et al. (2004) Small hypoattenuating hepatic lesions at contrast-enhanced CT: prognostic importance in patients with breast cancer. Radiology 233(3):667–673CrossRefPubMed Krakora GA, Coakley FV, Williams G, et al. (2004) Small hypoattenuating hepatic lesions at contrast-enhanced CT: prognostic importance in patients with breast cancer. Radiology 233(3):667–673CrossRefPubMed
Metadata
Title
Characterizing indeterminate liver lesions in patients with localized pancreatic cancer at the time of diagnosis
Authors
Manav Bhalla
Mohammed Aldakkak
Naveen M. Kulkarni
Stacy D. O’Connor
Michael O. Griffin Jr.
Kathleen K. Christians
Douglas B. Evans
Susan Tsai
Parag P. Tolat
Publication date
01-02-2018
Publisher
Springer US
Published in
Abdominal Radiology / Issue 2/2018
Print ISSN: 2366-004X
Electronic ISSN: 2366-0058
DOI
https://doi.org/10.1007/s00261-017-1404-0

Other articles of this Issue 2/2018

Abdominal Radiology 2/2018 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.